Key result
Intravenous verapamil suppresses Torsades de Pointes in 3 patients with AV block.
Why the study?
Does intravenous verapamil suppress Torsades de Pointes in patients with atrioventricular block?
Case Report (n=3)
Does intravenous verapamil suppress Torsades de Pointes in patients with atrioventricular block?
Intravenous verapamil may be of therapeutic value in suppressing Torsades de Pointes in patients with atrioventricular block.
Hypothesis-generating for verapamil in TdP with AV block; prospective trials needed before clinical adoption.
Experimental data have suggested a relation between Torsades de Pointes and early post-depolarization (EPD). We have studied the effect of intravenous verapamil in three patients with atrioventricular block (AVB) and Torsades de Pointes (TP), to obtain indirect evidence of slow membrane channel involvement in the TP mechanism. In two cases TP were completely suppressed and in one there was marked, albeit partial, suppression. In two cases verapamil did not shorten QT, while in the third suppression verapamil was related to junctional escape acceleration and QT shortening. In one of the cases where QT was not changed, the abolition of long pauses may have played a role in TP suppression. The affect of verapamil on TP in our patients is consistent with a combination of mechanisms, including direct membrane effects (EPD inhibition) and junctional pacemaker acceleration. Verapamil might be of therapeutic value in this clinical setting.
No takes yet. Share an insight, caveat, or question.
Cosío et al. (1991) conducted a case report in Atrioventricular block and Torsades de Pointes (n=3). Intravenous verapamil was evaluated on Suppression of Torsades de Pointes. Intravenous verapamil completely suppressed Torsades de Pointes in two patients and partially suppressed it in one patient with atrioventricular block.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: